TY - JOUR
T1 - Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis -stilbene diamines
T2 - A platform for the preparation of single-enantiomer cis -imidazolines for protein-protein inhibition
AU - Vara, Brandon A.
AU - Mayasundari, Anand
AU - Tellis, John C.
AU - Danneman, Michael W.
AU - Arredondo, Vanessa
AU - Davis, Tyler A.
AU - Min, Jaeki
AU - Finch, Kristin
AU - Guy, R. Kiplin
AU - Johnston, Jeffrey N.
PY - 2014/8
Y1 - 2014/8
N2 - The finding by scientists at Hoffmann-La Roche that cis-imidazolines could disrupt the protein-protein interaction between p53 and MDM2, thereby inducing apoptosis in cancer cells, raised considerable interest in this scaffold over the past decade. Initial routes to these small molecules (i.e., Nutlin-3) provided only the racemic form, with enantiomers being enriched by chromatographic separation using high-pressure liquid chromatography (HPLC) and a chiral stationary phase. Reported here is the first application of an enantioselective aza-Henry approach to nonsymmetric cis-stilbene diamines and cis-imidazolines. Two novel mono(amidine) organocatalysts (MAM) were discovered to provide high levels of enantioselection (>95% ee) across a broad range of substrate combinations. Furthermore, the versatility of the aza-Henry strategy for preparing nonsymmetric cis-imidazolines is illustrated by a comparison of the roles of aryl nitromethane and aryl aldimine in the key step, which revealed unique substrate electronic effects providing direction for aza-Henry substrate-catalyst matching. This method was used to prepare highly substituted cis-4,5-diaryl imidazolines that project unique aromatic rings, and these were evaluated for MDM2-p53 inhibition in a fluorescence polarization assay. The diversification of access to cis-stilbene diamine-derived imidazolines provided by this platform should streamline their further development as chemical tools for disrupting protein-protein interactions.
AB - The finding by scientists at Hoffmann-La Roche that cis-imidazolines could disrupt the protein-protein interaction between p53 and MDM2, thereby inducing apoptosis in cancer cells, raised considerable interest in this scaffold over the past decade. Initial routes to these small molecules (i.e., Nutlin-3) provided only the racemic form, with enantiomers being enriched by chromatographic separation using high-pressure liquid chromatography (HPLC) and a chiral stationary phase. Reported here is the first application of an enantioselective aza-Henry approach to nonsymmetric cis-stilbene diamines and cis-imidazolines. Two novel mono(amidine) organocatalysts (MAM) were discovered to provide high levels of enantioselection (>95% ee) across a broad range of substrate combinations. Furthermore, the versatility of the aza-Henry strategy for preparing nonsymmetric cis-imidazolines is illustrated by a comparison of the roles of aryl nitromethane and aryl aldimine in the key step, which revealed unique substrate electronic effects providing direction for aza-Henry substrate-catalyst matching. This method was used to prepare highly substituted cis-4,5-diaryl imidazolines that project unique aromatic rings, and these were evaluated for MDM2-p53 inhibition in a fluorescence polarization assay. The diversification of access to cis-stilbene diamine-derived imidazolines provided by this platform should streamline their further development as chemical tools for disrupting protein-protein interactions.
UR - http://www.scopus.com/inward/record.url?scp=84905406308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905406308&partnerID=8YFLogxK
U2 - 10.1021/jo501003r
DO - 10.1021/jo501003r
M3 - Article
C2 - 25017623
AN - SCOPUS:84905406308
SN - 0022-3263
VL - 79
SP - 6913
EP - 6938
JO - Journal of Organic Chemistry
JF - Journal of Organic Chemistry
IS - 15
ER -